Maraviroc-d6

• UNSPSC Description:

  Maraviroc-d6 (UK-427857-d6) is the deuterium labeled Maraviroc. Maraviroc (UK-427857) is a selective CCR5 antagonist with activity against human HIV[1][2].

• Target Antigen:

  CCR; HIV; Isotope-Labeled Compounds

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Anti-infection;GPCR/G Protein;Immunology/Inflammation;Others

• Applications:

  Metabolism-protein/nucleotide metabolism

• Field of Research:

  Inflammation/Immunology; Cancer; Endocrinology

• Solubility:

  10 mM in DMSO

• Smiles:

  C(C[C@H](NC(=O)C1CCC(F)(F)CC1)C2=CC=CC=C2)N3[C@@H]4C[C@@H](C[C@H]3CC4)N5C(C(C([2H])([2H])[2H])C([2H])([2H])[2H])=NN=C5C

• Molecular Weight:

  519.70

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.|[2]Dorr P, et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother. 2005 Nov;49(11):472|[3]Mencarelli A, et al. Highly specific blockade of CCR5 inhibits leukocyte trafficking and reduces mucosal inflammation in murine colitis. Sci Rep. 2016 Aug 5;6:30802.|[4]Romero-Sánchez MC, et al. Effect of maraviroc on HIV-disease progression-related biomarkers. Antimicrob Agents Chemother. 2012 Nov;56(11):5858-64.|[5]Huilin Mou, et al. NRSF and CCR5 Established Neuron-glia Communication during Acute and Chronic Stresses. Journal of Drug Metabolism & Toxicology. January 10, 2016.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  1033699-22-7